Clinical Development Network Across Global Newsroom Participants Submit an RFP

Solutions · Early Development Strategy | Clinical Development Planning | Guosa Life Sciences

Early Decisions Shape Clinical Success

Strategic Planning for Confident Clinical Development

Every successful clinical development program begins long before the first participant is enrolled. Scientific strategy, regulatory planning, operational readiness and risk management established during early development influence timelines, costs, quality and the likelihood of regulatory and commercial success.

Submit an RFP

Home/Solutions/Early Development Strategy | Clinical Development Planning | Guosa Life Sciences

Overview

Strategic Planning for Confident Clinical Development

Guosa Life Sciences partners with sponsors to transform promising scientific concepts into practical development strategies through integrated planning, multidisciplinary expertise and evidence-informed decision-making.

Our Early Development Strategy services help organizations navigate complexity, reduce uncertainty and establish a strong foundation for every stage of development.

Early-phase clinical development and biometrics planning

Capabilities

What We Deliver

Strategic Planning

Development strategy
Regulatory pathway planning
Feasibility and country strategy
Operational readiness
Risk identification and mitigation

Program Foundations

Protocol strategy
Target product profile alignment
Vendor and partner strategy
Budget and timeline modeling

Lifecycle

Where This Fits

ConceptScientific Rationale

PlanDevelopment Strategy

DesignProtocol and Feasibility

ReadyOperational Setup

SubmitRegulatory Applications

LaunchStudy Start-Up

The GLS Advantage

Strengthened by the Whole Enterprise

Every solution delivered by Guosa Life Sciences is strengthened by the broader enterprise. Our operational teams are supported by evidence-based Insights, professional development through GLS Academy, collaborative partnerships within the Clinical Development Network and a quality-driven delivery model, enabling scientifically sound, operationally efficient and scalable solutions.

Explore the Enterprise

Evidence-based Insights
GLS Academy development
Clinical Development Network
Integrated quality systems
Technology-enabled delivery
Global operational reach

The capability

What We Actually Do

We help sponsors decide what the first studies in humans should be and where they should run: development strategy, first-in-human study design, dose selection rationale, starting dose justification, safety monitoring design, and the operational readiness assessment that determines whether a chosen unit can actually deliver the protocol.

Early-phase work is unforgiving of optimism. A protocol that assumes intensive sampling, rapid bioanalysis and same-day safety review requires a unit that has done it before, with the staffing and laboratory access to sustain it. We assess that capability against the specific protocol rather than against a general reputation.

Regulatory considerations

First-in-human enabling packages and phase I readiness

First-in-human submissions carry an evidentiary burden that later-phase studies do not. Authorities expect a clear rationale for the starting dose and the dose escalation scheme, an explicit justification of the safety monitoring plan against the identified risks, and a stopping rule framework that is defensible in advance rather than negotiated after an event.

Where a first-in-human study is conducted outside the sponsor's home jurisdiction, the qualification question becomes institutional rather than regional. What matters is whether a specific unit holds current accreditation, has demonstrated the relevant capability, maintains the laboratory access the protocol needs, and can evidence its investigator and staff training. That assessment is the subject of our published framework on institutional qualification, and it is the approach we apply.

How an engagement runs

The Sequence

1. Development strategy

Target product profile, development path options and the evidence each requires, with go and no-go criteria defined.

2. Study design

First-in-human design, dose rationale, safety monitoring and stopping rules, prepared for regulatory scrutiny.

3. Site and unit qualification

Assessment of candidate phase I units against the specific protocol, covering capability, laboratory access, staffing and documented track record.

4. Enabling package

Assembly of the submission package and management of scientific advice or pre-submission engagement where available.

What you receive

Deliverables

A development strategy with defined decision criteria. A first-in-human protocol with documented dose and safety rationale. A qualification assessment of candidate units. A submission-ready enabling package.

Evidence and context

The Research Behind This Work

Our operating assumptions are published rather than asserted. The Future of Clinical Trials in Africa sets out why study performance is increasingly determined by ecosystem maturity rather than site selection, and The Untapped Advantage makes the case that institutions, not regions, are the right unit of qualification. Both are available in full, with executive briefs for readers who want the argument in a shorter form.

The Future of Clinical Trials in Africa The Untapped Advantage

Consulting and Advisory

Strategic advisory across your program.

Explore

Regulatory Affairs

Global regulatory strategy and submissions.

Explore

Clinical Operations

Phase I–IV delivery.

Explore

Data and Biostatistics

Design endpoints and analysis.

Explore

FAQ

Common Questions

How early should we engage GLS?

As early as possible, decisions made before first-patient-in shape timelines, cost and success. We support planning from scientific concept through study start-up.

Do you support first-in-human studies?

Yes. Our teams combine early-phase operational experience with regulatory and safety expertise to support first-in-human and early-phase programs.

Let's Discuss Your Program

Tell us about your objectives and our multidisciplinary team will scope an integrated, flexible solution.

Submit an RFP

Early Decisions Shape Clinical Success

Strategic Planning for Confident Clinical Development

What We Deliver

Strategic Planning

Program Foundations

Where This Fits

Strengthened by the Whole Enterprise

What We Actually Do

First-in-human enabling packages and phase I readiness

The Sequence

1. Development strategy

2. Study design

3. Site and unit qualification

4. Enabling package

Deliverables

The Research Behind This Work

Explore Related Capabilities

Consulting and Advisory

Regulatory Affairs

Clinical Operations

Data and Biostatistics

Common Questions

Let's Discuss Your Program